| α-Synuclein amyloids hijack prion protein to gain cell entry, facilitate cell-to-cell spreading and block prion replication S Aulić, L Masperone, J Narkiewicz, E Isopi, E Bistaffa, E Ambrosetti, ... Scientific reports 7 (1), 10050, 2017 | 138 | 2017 |
| Role of Rad51 and DNA repair in cancer: A molecular perspective E Laurini, D Marson, A Fermeglia, S Aulic, M Fermeglia, S Pricl Pharmacology & therapeutics 208, 107492, 2020 | 101 | 2020 |
| Defined α-synuclein prion-like molecular assemblies spreading in cell culture S Aulić, TTN Le, F Moda, S Abounit, S Corvaglia, L Casalis, S Gustincich, ... BMC neuroscience 15, 1-12, 2014 | 91 | 2014 |
| Computational alanine scanning and structural analysis of the SARS-CoV-2 spike protein/angiotensin-converting enzyme 2 complex E Laurini, D Marson, S Aulic, M Fermeglia, S Pricl ACS nano 14 (9), 11821-11830, 2020 | 75 | 2020 |
| A fluorescent styrylquinoline with combined therapeutic and diagnostic activities against Alzheimer’s and Prion diseases M Staderini, S Aulić, M Bartolini, HNA Tran, V González-Ruiz, DI Pérez, ... ACS Medicinal Chemistry Letters 4 (2), 225-229, 2013 | 71 | 2013 |
| Small‐Molecule Theranostic Probes: A Promising Future in Neurodegenerative Diseases S Aulić, ML Bolognesi, G Legname International journal of cell biology 2013 (1), 150952, 2013 | 53 | 2013 |
| Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies E Laurini, D Marson, S Aulic, A Fermeglia, S Pricl Scientific Reports 11 (1), 20274, 2021 | 48 | 2021 |
| Computational mutagenesis at the SARS-CoV-2 spike protein/angiotensin-converting enzyme 2 binding interface: comparison with experimental evidence E Laurini, D Marson, S Aulic, A Fermeglia, S Pricl ACS nano 15 (4), 6929-6948, 2021 | 42 | 2021 |
| Design, synthesis and antitubercular activity of 4-alkoxy-triazoloquinolones able to inhibit the M. tuberculosis DNA gyrase A Carta, A Bua, P Corona, S Piras, I Briguglio, P Molicotti, S Zanetti, ... European Journal of Medicinal Chemistry 161, 399-415, 2019 | 27 | 2019 |
| Synthetic prions with novel strain-specified properties F Moda, TN T. Le, S Aulić, E Bistaffa, I Campagnani, T Virgilio, A Indaco, ... PLoS pathogens 11 (12), e1005354, 2015 | 27 | 2015 |
| Breast cancer nanomedicine market update and other industrial perspectives of nanomedicine S Aulic, D Marson, E Laurini, M Fermeglia, S Pricl Nanomedicines for Breast Cancer Theranostics, 371-404, 2020 | 22 | 2020 |
| Synthetic prions and other human neurodegenerative proteinopathies NTT Le, J Narkiewicz, S Aulić, G Salzano, HT Tran, D Scaini, F Moda, ... Virus research 207, 25-37, 2015 | 22 | 2015 |
| Dichloro-phenyl-benzotriazoles: A new selective class of human respiratory syncytial virus entry inhibitors S Piras, G Sanna, A Carta, P Corona, R Ibba, R Loddo, S Madeddu, ... Frontiers in chemistry 7, 247, 2019 | 21 | 2019 |
| Multiscale molecular modelling for the design of nanostructured polymer systems: industrial applications M Fermeglia, A Mio, S Aulic, D Marson, E Laurini, S Pricl Molecular Systems Design & Engineering 5 (9), 1447-1476, 2020 | 18 | 2020 |
| Some things old, new and borrowed: Delivery of dabrafenib and vemurafenib to melanoma cells via self-assembled nanomicelles based on an amphiphilic dendrimer M Russi, R Valeri, D Marson, C Danielli, F Felluga, A Tintaru, N Skoko, ... European Journal of Pharmaceutical Sciences 180, 106311, 2023 | 16 | 2023 |
| Evolution from covalent to self-assembled PAMAM-based dendrimers as nanovectors for siRNA delivery in cancer by coupled in silico-experimental studies. Part I: Covalent siRNA … D Marson, E Laurini, S Aulic, M Fermeglia, S Pricl Pharmaceutics 11 (7), 351, 2019 | 16 | 2019 |
| 9-Aminoacridine-based agents impair the bovine viral diarrhea virus (BVDV) replication targeting the RNA-dependent RNA polymerase (RdRp) R Loddo, V Francesconi, E Laurini, S Boccardo, S Aulic, M Fermeglia, ... Bioorganic & Medicinal Chemistry 26 (4), 855-868, 2018 | 16 | 2018 |
| Evolution from covalent to self-assembled PAMAM-based dendrimers as nanovectors for siRNA delivery in cancer by coupled in silico-experimental studies. Part II: Self-assembled … E Laurini, D Marson, S Aulic, M Fermeglia, S Pricl Pharmaceutics 11 (7), 324, 2019 | 11 | 2019 |
| Rational approach to an antiprion compound with a multiple mechanism of action ML Bolognesi, S Bongarzone, S Aulic, HN Ai Tran, F Prati, P Carloni, ... Future Medicinal Chemistry 7 (16), 2113-2120, 2015 | 10 | 2015 |
| The fellowship of the RING: BRCA1, its partner BARD1 and their liaison in DNA repair and cancer M Russi, D Marson, A Fermeglia, S Aulic, M Fermeglia, E Laurini, S Pricl Pharmacology & Therapeutics 232, 108009, 2022 | 9 | 2022 |
